Apellis Pharmaceuticals, Inc. (APLS) Misses Q3 EPS by 31c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Apellis Pharmaceuticals Reports Third Quarter 2022 Financial Results
November 7, 2022 4:05 PM ESTPlans to submit 24-month Phase 3 data to the FDA for intravitreal pegcetacoplan for geographic atrophy (GA); expected PDUFA target action date in February 2023EU marketing authorization application submission on track for December 2022Reported 24-month data with pegcetacoplan in GA showing increased effects over time and continued favorable safety profileAchieved $17.7 million in Q3 2022 EMPAVELI® (pegcetacoplan) U.S. net product revenuesCash and investments of $708.6 million as of Sept. 30, 2022; expected cash runway into Q1 2024Conference call scheduled today at 4:30 p.m. ET
WALTHAM, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) --... More
